Compare Anti-VEGF

4 products »

close Created with Sketch.

Lucentis

Genentech, Inc.

Lucentis (ranibizumab injection) is a a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV).

At-a-Glance
  • Mechanism of Action: Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
  • Dosage:
    • Neovascular (Wet) Age-Related Macular Degeneration (AMD):  0.5 mg (0.05 mL) to be administered by intravitreal injection once a month (approximately 28 days).
    • Macular Edema Following Retinal Vein Occlusion (RVO): 0.5 mg (0.05 mL) to be administered by intravitreal injection once a month (approximately 28 days).
    • Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR): 0.3 mg (0.05 mL) to be administered by intravitreal injection once a month (approximately 28 days).
    • Myopic Choroidal Neovascularization (mCNV): 0.5 mg (0.05 mL) to be initially administered by intravitreal injection once a month (approximately 28 days) for up to three months. Patients may be retreated if needed.

Details

FDA

Yes

CE Mark

Not specified

Active Ingredients

Ranibizumab

Application

Intravitreal

Status

Prescription

Strength

Not specified

Company Information

Contact the company for additional information, availability, or pricing:

Genentech, Inc.

www.gene.com

1 DNA Way

South San Franciso, CA 94080